A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients
- Conditions
- FSGS
- Registration Number
- NCT01468493
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Brief Summary
The purpose of this study is to determine whether the improved responsiveness to treatment achieved by CsA in patients with steroid-resistant or steroid-dependent FSGS could be explained by CsA's inhibitory action on the circulating suPAR expression.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 90
- Age at entry is between 14 and 70 years
- biopsy-proven primary FSGS
- proteinuria >=3 g/day
- without corticosteroids or CsA treatment before entry
- Chronic Inflammatory Diseases
- malignant tumor
- diabetes mellitus
- contraindications for the treatment of corticosteroids or CsA treatment
- untolerate to or unwilling to accept corticosteroids or CsA treatment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method serum suPAR level when proteinuria reduction >=50% or complete remission 6 months after steriod alone or CsA plus steriod treatment serum suPAR level when proteinuria reduction of \>=50% or complete remission occurs within \<=6 months of steroid alone or CsA plus steroid treatment
- Secondary Outcome Measures
Name Time Method serum suPAR level after 6 months of steroid or CsA treatment without remission 6 months after steroid alone or CsA plus steroid treatment serum suPAR level after 6 months of steroid alone or CsA plus steroid treatment without remission
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Nephrology Dept.,Guangdong General Hospital
🇨🇳Guangzhou, Guangdong, China